Titan Pharmaceuticals
Delaware corporation
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
0
confidence 55 % · metrics-v1
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
0
confidence 60 % · metrics-v1
Corporate Change Index
0
confidence 64 % · cci-v1
9 active sensors·1 observation·0 historical changes·0 structured events·historical coverage 91 %·observed since 2026-09-13
Compare Titan Pharmaceuticals with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies